Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oragenics Inc.

www.oragenics.com

Latest From Zimmer Biomet Holdings Inc.

US Approvals Analysis: FDA Delivers Strong Half-Year Volumes

US FDA Device-approval volumes were strong during the first half of 2017 for all review pathways. Medtronic and Siemens have so far captured the most 510(k) clearances, with Cook close behind. That and more from Medtech Insight's Approvals Tracker.

Approvals Innovation

Judge Rules For Enhanced Damages In Zimmer-Stryker Patent Spat

The case had gone to the US Supreme Court due to a dispute over the standards for enhanced damages. Zimmer, which was ordered to pay almost $250m in costs and penalties, expects to appeal the verdict.

Legal Issues Intellectual Property

'Open Payments' Peek: Device, DX Company Payments To Physicians Slightly Down In 2016

The latest updates to the US Open Payments database show spending by device and diagnostics firms on physician royalties, consulting fees, education, research and more was a bit less in 2016 compared to 2015, but still substantial. Top "general payment" spending came from Medtronic, Zimmer Biomet, Johnson & Johnson, Stryker, Smith & Nephew and Intuitive Surgical; while top "research payments" were reported by Edwards Lifesciences, Boston Scientific, and Abbott Laboratories, according to the CMS database.

Regulation Compliance

Zimmer Biomet Names New CEO Amid Disappointing Earnings

David Dvorak has stepped down as president and CEO, and from the company's board, and CFO Daniel P. Florin will take over as interim CEO, the orthopedics giant announced July 11. The company also announced preliminary second-quarter sales and earnings that, while within the previously projected range, included disappointments for several product lines.

Companies Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • ONI BioPharma Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Oragenics Inc.
  • Senior Management
  • Alan Joslyn, PhD, Pres. & CEO
    Michael Sullivan, CFO
    Martin Handfield, PhD, VP, Research
  • Contact Info
  • Oragenics Inc.
    Phone: (813) 286-7900
    4902 Eisenhower Blvd., Ste. 125
    Tampa, FL 33634
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register